Inhibition of cyclo-oxygenase 2 (COX 2) may represent a potential anti-cancer strategy. It has already been observed that people who receive long-term therapy with NSAIDs (typically for arthritis) have a lower incidence of colon cancer.*Data presented at the 35th Annual Meeting of the American Society of Clinical Oncology, [Atlanta, US; May 1999], confirm the COX 2/bcl-2 gene connection, and suggest how a COX 2 inhibitor may fit into the current antineoplastic armamentarium.